Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity

British Journal of Cancer

Volumn 86, Issue 7, 2002, Pages 1162-1168

  Fischel, J L ^a   Formento, P ^a   Ciccolini, J ^b   Rostagno, P ^a   Etienne, M C ^a   Catalin, J ^b   Milano, Gerard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b Pharmacokinetics Unit   (France)

Author keywords

5 fluorouracil; Drug interactions; Oxaliplatin; WiDr cell line

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL MEMBRANE PERMEABILITY; COLORECTAL CANCER; CYTOTOXICITY; DRUG DEGRADATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL MEMBRANE; COLONIC NEOPLASMS; DNA DAMAGE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PERMEABILITY; THYMIDYLATE SYNTHASE; TOXICITY TESTS; TUMOR CELLS, CULTURED;

EID: 85047698210     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600185     Document Type: Article

References (36)

1. Bimonthly high-dose leucovorin, 5 fluorouracil infusion and oxaliplation (FOLFOX 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
2. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates
3. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil
4. Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells
5. Evaluation of tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensibility testing
6. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma
7. Quantitative analysis of dose-effects relationships: The combined effects of multiple drugs or enzyme inhibitors
8. Enhanced antitumour activity of 5-fluorouracil in combination with 2′-deoxyinosine in human colorectal cell lines and human colon cancer xenografts
9. Leucovorin and fluorouracil with or without oxaliplation as first-line treatment in advanced colorectal cancer
10. Oral DPD-inhibitory fluoropyrimidine drugs
11. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high dose leucovorin every two weeks (LV 5FU 2 regimen): A clinical dose-finding and pharmacokinetic study in patient with pre-treated metastatic colorectal cancer
12. Response to fluorouracil therapy in cancer patients: The role of tumoural dihydropyrimidine dehydrogenase activity
13. Critical factors for optimizing for 5-fluorouracil-folinic acid association in cancer chemotherapy
14. Dihydropyrimidine dehydrogenase: A tumoural target for fluorouracil modulation. Experimental data
15. Search for the optimal schedule for the oxaliplatin/5 fluorouracil association modulated or not by folinic acid: Preclinical data
16. Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplation in advanced colorectal cancer patients
17. Clinical pharmacokinetics of oxaliplatin: A critical review
18. 5 Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development
19. Thymidine kinase, thymidilate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen
20. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: A novel class of oral antineoplastic agents
21. New developments and approaches in the platinum arena
22. Mechanism of the cytotoxic synergism of fluorouropyrimidines and folinic acid in mouse leukemic cells
23. Folic acid. An update with new recommended daily allowances
24. Pharmacokinetics of 5-fluorouracil in combination with cisplatin: Evidence for drug interaction
25. Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs
26. Schedule-dependent enhancement of the cytotoxicity of fluoropyridimes to human carcinoma cells in the presence of folinic acid
27. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves
28. Pharmacokinetics interaction between 5-fluorouracil and oxaliplatin
29. P53 dependence of FAS induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines
30. Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil
31. Down regulation of Thymidilate Synthase gene expression after Oxaliplation administration: Implications for the synergistic activity of the sequential Oxaliplatin/5FU in sensitive and 5FU resistant cell lines
32. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG 337 in human colon, breast and ovarian cancers
33. Methods for thymidylate synthase pharmacokinetics: Serial biopsy, free and total TS, FdUMP and dUMP, and H4 pte Glu and CH2-H4 Pte Glu assays
34. The medical treatment of colorectal cancer: Actual status and new developments
35. An integrated set of methods for routine flow cytometry DNA analysis
36. Platinum-folate compounds: Synthesis, properties and biological activity